Richard Looby
About Richard Looby
Richard Looby is an Associate Director at Wave Life Sciences, where he has worked since 2020. He has extensive experience in the pharmaceutical industry, having held senior positions at several companies and a strong background in chemistry and process development.
Current Role at Wave Life Sciences
Richard Looby serves as Associate Director at Wave Life Sciences, a position he has held since 2020. He works in Lexington, Massachusetts, where he applies his extensive expertise in oligonucleotide synthesis and process development. In this role, he continues to contribute to the company's objectives in drug discovery and development.
Previous Experience at Wave Life Sciences
Prior to his current role, Richard Looby worked at Wave Life Sciences as a Senior Scientist from 2016 to 2020. During his tenure in Cambridge, MA, he directed quality action teams and safety initiatives, demonstrating his leadership capabilities and commitment to maintaining high standards in research and development.
Career Background in Pharmaceutical Research
Richard Looby has a diverse background in pharmaceutical research, having held positions at several organizations. He was a Senior Research Investigator at Bristol Myers Squibb from 2006 to 2008 and a Senior Principal Scientist at Anchor Therapeutics from 2008 to 2012. His experience also includes a role as Senior Staff Scientist at Epix Pharmaceuticals from 1997 to 2006.
Educational Background in Chemistry
Richard Looby studied Chemistry at the University of Massachusetts, Amherst, where he earned a Bachelor of Science (B.S.) degree from 1985 to 1989. He also pursued graduate courses in Chemistry at Northeastern University, enhancing his knowledge and skills in the field.
Expertise in Oligonucleotide Synthesis
Richard Looby possesses strong expertise in oligonucleotide synthesis and multi-step organic synthesis. His focus includes both solid phase and solution phase synthesis, which are critical techniques in the development of therapeutic agents. He has contributed to discovery and process development objectives, including the transfer of processes to contract manufacturing organizations for GMP clinical material.